Mustafa Bashir, M.D.

Mustafa R. Bashir, M.D.

  • Associate Professor of Radiology and Associate Professor in the Department of Medicine, Gastroenterology
  • Director, MRI
  • Director, Center for Advanced Magnetic Resonance Imaging
  • Bashir Lab for Liver Imaging Research
  • Abdominal Imaging
Address DUMC Box 3808
Durham, NC 27710
Telephone 919-684-7366
Fax 919-684-7129
  • M.D., University of Iowa College of Medicine, 2004
  • Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, 2009
  • Abdominal Imaging and Intervention, Duke University Medical Center, 2010
National Roles
  • Associate Editor for Continuing Medical Education, Journal of Magnetic Resonance Imaging
  • Annual Meeting Planning Committee, International Society of Magnetic Resonance in Medicine
  • LI-RADS Steering Committee Member and Research & Development Working Group Chair
  • Scientific Program GI Subcommittee, Radiological Society of North America
  • BS, University of Nebraska - Lincoln
  • MD, University of Iowa College of Medicine
Clinical Interests
  • Magnetic resonance imaging
  • Hepatobiliary imaging
  • Workflow
  • Quantitative imaging
  • Image-guided percutaneous interventions/procedures
  • Research Interests
  • Quantitative techniques in MRI
  • Diffuse liver disease
  • Hepatobiliary imaging
  • CT and MR perfusion
  • Image postprocessing
    • Mitchell DG, Bashir MR, Sirlin CB. Management implications and outcomes of LI-RADS-2, -3, -4, and -M category observations. doi: 10.1007/s00261-017-1251-z. 2017 Aug 4; Abstract
    • Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. doi: 10.1002/jmri.25625. 2017 Aug;46(2):338-353 Abstract
    • Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, Brunt EM, Kleiner DE, Doo E, Van Natta ML, Lavine JE, Neuschwander-Tetri BA, Sanyal A, Loomba R, Sirlin CB, NASH Clinical Research Network.. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. pii: S0016-5085(17)35739-6. doi: 10.1053/j.gastro.2017.06.005. 2017 Jun 15; Abstract
    • Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, Dosa E, Finn JP, Gahramanov S, Harisinghani M, Macdougall I, Neuwelt A, Vasanawala SS, Ambady P, Barajas R, Cetas JS, Ciporen J, DeLoughery TJ, Doolittle ND, Fu R, Grinstead J, Guimaraes AR, Hamilton BE, Li X, McConnell HL, Muldoon LL, Nesbit G, Netto JP, Petterson D, Rooney WD, Schwartz D, Szidonya L, Neuwelt EA. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. doi: 10.1016/j.kint.2016.12.037. 2017 Jul;92(1):47-66 Abstract
    • Allen BC, Lugauer F, Nickel D, Bhatti L, Dafalla RA, Dale BM, Jaffe TA, Bashir MR. Effect of a Low-Rank Denoising Algorithm on Quantitative Magnetic Resonance Imaging-Based Measures of Liver Fat and Iron. doi: 10.1097/RCT.0000000000000535. 2017 May Jun;41(3):412-416 Abstract
    • Elsayes KM, Kielar AZ, Agrons MM, Szklaruk J, Tang A, Bashir MR, Mitchell DG, Do RK, Fowler KJ, Chernyak V, Sirlin CB. Liver Imaging Reporting and Data System: an expert consensus statement. doi: 10.2147/JHC.S125396. 2017;4:29-39 Abstract
    • Fananapazir G, Bashir MR, Corwin MT, Lamba R, Vu CT, Troppmann C. Comparison of ferumoxytol-enhanced MRA with conventional angiography for assessment of severity of transplant renal artery stenosis. doi: 10.1002/jmri.25421. 2017 Mar;45(3):779-785 Abstract
    • Polanec SH, Bickel H, Baltzer PA, Thurner P, Gittler F, Hodge JC, Bashir MR, Ba-Ssalamah A. Respiratory motion artifacts during arterial phase imaging with gadoxetic acid: Can the injection protocol minimize this drawback? doi: 10.1002/jmri.25657. 2017 Feb 9; Abstract
    • McClellan TR, Motosugi U, Middleton MS, Allen BC, Jaffe TA, Miller CM, Reeder SB, Sirlin CB, Bashir MR. Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial. doi: 10.1148/radiol.2016160482. 2017 Feb;282(2):361-368 Abstract
    • Sofue K, Burke LM, Nilmini V, Alagiyawanna M, Muir AJ, Choudhury KR, Jaffe TA, Semelka RC, Bashir MR. Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5. doi: 10.1002/jmri.25627. 2017 Jan 13; Abstract
    • Bashir MR, Gupta RT, Davenport MS, Allen BC, Jaffe TA, Ho LM, Boll DT, Merkle EM. Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging. 2013 Feb;37(2):398-406.
    • Bashir MR, Dale BM, Merkle EM, Boll DT. Automated liver sampling using a gradient dual-echo Dixon-based technique. Magn Reson Med. 2012 May;67(5):1469-77.
    • Bashir MR, Merkle EM, Smith AD, Boll DT. Hepatic MR imaging for in vivo differentiation of steatosis, iron deposition and combined storage disorder: single-ratio in/opposed phase analysis vs. dual-ratio Dixon discrimination. Eur J Radiol. 2012 Feb;81(2):e101-9.
    • Bashir MR, Merkle EM. Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol. 2011 Feb;21(2):291-4.
    • Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, Merkle EM. Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? doi: 10.1002/jmri.22850. 2012 Mar;35(3):611-6 Abstract
    • Burke LM, Sofue K, Alagiyawanna M, Nilmini V, Muir AJ, Choudhury KR, Semelka RC, Bashir MR. Natural history of liver imaging reporting and data system category 4 nodules in MRI. doi: 10.1007/s00261-016-0762-3. 2016 Sep;41(9):1758-66 Abstract
    • Hernando D, Sharma SD, Aliyari Ghasabeh M, Alvis BD, Arora SS, Hamilton G, Pan L, Shaffer JM, Sofue K, Szeverenyi NM, Welch EB, Yuan Q, Bashir MR, Kamel IR, Rice MJ, Sirlin CB, Yokoo T, Reeder SB. Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantom. doi: 10.1002/mrm.26228. 2017 Apr;77(4):1516-1524 Abstract
    • Sofue K, Zhong X, Nickel MD, Dale BM, Bashir MR. Stability of liver proton density fat fraction and changes in R 2* measurements induced by administering gadoxetic acid at 3T MRI. doi: 10.1007/s00261-016-0728-5. 2016 Aug;41(8):1555-64 Abstract
    • Vasanawala SS, Nguyen KL, Hope MD, Bridges MD, Hope TA, Reeder SB, Bashir MR. Safety and technique of ferumoxytol administration for MRI. doi: 10.1002/mrm.26151. 2016 May;75(5):2107-11 Abstract
    • Corwin MT, Fananapazir G, Jin M, Lamba R, Bashir MR. Differences in Liver Imaging and Reporting Data System Categorization Between MRI and CT. doi: 10.2214/AJR.15.14788. 2016 Feb;206(2):307-12 Abstract
    • Sofue K, Sirlin CB, Allen BC, Nelson RC, Berg CL, Bashir MR. How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. doi: 10.1002/jmri.25094. 2016 Jun;43(6):1337-45 Abstract
    • Sofue K, Marin D, Jaffe TA, Nelson RC, Bashir MR. Can combining triple-arterial phase acquisition with fluoroscopic triggering provide both optimal early and late hepatic arterial phase images during gadoxetic acid-enhanced MRI? doi: 10.1002/jmri.25079. 2016 May;43(5):1073-81 Abstract
    • Gardner CS, Bashir MR, Marin D, Nelson RC, Choudhury KR, Ho LM. Diagnostic performance of imaging criteria for distinguishing autoimmune cholangiopathy from primary sclerosing cholangitis and bile duct malignancy. doi: 10.1007/s00261-015-0543-4. 2015 Oct;40(8):3052-61 Abstract
    • Sofue K, Mileto A, Dale BM, Zhong X, Bashir MR. Interexamination repeatability and spatial heterogeneity of liver iron and fat quantification using MRI-based multistep adaptive fitting algorithm. doi: 10.1002/jmri.24922. 2015 Nov;42(5):1281-90 Abstract
    • Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, Sirlin CB, Bashir MR. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. doi: 10.2214/AJR.14.12986. 2015 Mar;204(3):527-35 Abstract
    • Bashir MR, Zhong X, Nickel MD, Fananapazir G, Kannengiesser SA, Kiefer B, Dale BM. Quantification of hepatic steatosis with a multistep adaptive fitting MRI approach: prospective validation against MR spectroscopy. doi: 10.2214/AJR.14.12457. 2015 Feb;204(2):297-306 Abstract
    • Bashir MR, Huang R, Mayes N, Marin D, Berg CL, Nelson RC, Jaffe TA. Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. doi: 10.1002/jmri.24793. 2015 Aug;42(2):305-14 Abstract
    • Fananapazir G, Bashir MR, Marin D, Boll DT. Computer-aided liver volumetry: performance of a fully-automated, prototype post-processing solution for whole-organ and lobar segmentation based on MDCT imaging. doi: 10.1007/s00261-014-0276-9. 2015 Jun;40(5):1203-12 Abstract
    • Bashir MR, Castelli P, Davenport MS, Larson D, Marin D, Hussain HK, Jaffe TA. Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium. doi: 10.1148/radiol.14140386. 2015 Jan;274(1):141-8 Abstract
    • Davenport MS, Bashir MR, Pietryga JA, Weber JT, Khalatbari S, Hussain HK. Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact. doi: 10.2214/AJR.13.11587. 2014 Oct;203(4):796-802 Abstract
    • Heye T, Boll DT, Reiner CS, Bashir MR, Dale BM, Merkle EM. Impact of precontrast T10 relaxation times on dynamic contrast-enhanced MRI pharmacokinetic parameters: T10 mapping versus a fixed T10 reference value. 2014 May;39(5):1136-45. Abstract
    • Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. doi: 10.1002/jmri.24691. 2015 Apr;41(4):884-98 Abstract